Nunzia Pharmaceutical Corporation
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Com… Read more
Nunzia Pharmaceutical Corporation (NUNZ) - Total Liabilities
Latest total liabilities as of September 2022: $226.69K USD
Based on the latest financial reports, Nunzia Pharmaceutical Corporation (NUNZ) has total liabilities worth $226.69K USD as of September 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nunzia Pharmaceutical Corporation - Total Liabilities Trend (2004–2021)
This chart illustrates how Nunzia Pharmaceutical Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nunzia Pharmaceutical Corporation Competitors by Total Liabilities
The table below lists competitors of Nunzia Pharmaceutical Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trillium Acquisition Corp
V:TCK-P
|
Canada | CA$-17.62K |
|
Pomvom
TA:PMVM
|
Israel | ILA38.63 Million |
|
Bruton Limited
OL:BRUT
|
Norway | Nkr56.00K |
|
OMNIA HOLD (OHZ.SG)
STU:OHZ
|
Germany | €7.49 Billion |
|
Ashtead Technology Holdings PLC
LSE:AT
|
UK | GBX188.60 Million |
|
LIBERTY INT QVC-A (LB3A.SG)
STU:LB3A
|
Germany | €10.29 Billion |
Liability Composition Analysis (2004–2021)
This chart breaks down Nunzia Pharmaceutical Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nunzia Pharmaceutical Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nunzia Pharmaceutical Corporation (2004–2021)
The table below shows the annual total liabilities of Nunzia Pharmaceutical Corporation from 2004 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-12-31 | $99.31K | +172.79% |
| 2020-12-31 | $36.40K | +61.26% |
| 2019-12-31 | $22.57K | -92.32% |
| 2018-12-31 | $293.97K | +6.75% |
| 2017-12-31 | $275.39K | +395.31% |
| 2010-12-31 | $55.60K | -98.57% |
| 2009-12-31 | $3.88 Million | +3.86% |
| 2008-12-31 | $3.73 Million | +3.72% |
| 2007-12-31 | $3.60 Million | +3.57% |
| 2006-12-31 | $3.48 Million | +3.42% |
| 2005-12-31 | $3.36 Million | +2.07% |
| 2004-12-31 | $3.29 Million | -- |